Table 3.
Parameters used in sensitivity analysis
| Parameter | Cost-effectiveness scenario | ||
|---|---|---|---|
| Baseline | Pessimistic | Optimistic | |
| Spontaneous unaided yearly quit rate (%) | 1.5 | 2.5 | 0.5 |
| Six-month nonsmoking rates (%)a | |||
| Web with varenicline | 29.2 | 24.7 | 33.6 |
| PTC with varenicline | 32.6 | 28.0 | 37.2 |
| PTC-Web with varenicline | 32.1 | 27.5 | 36.7 |
| Relapse rate from 6 months to 12 months (%) | 22.0 | 26.4 | 17.6 |
| Relapse rate for 12-month quitters (%) | 37.0 | 44.4 | 29.6 |
| Cost of Web ($) | 120.10 | 144.12 | 96.08 |
| Cost of PTC ($) | 226.95 | 272.34 | 181.56 |
| Cost of PTC-Web ($) | 266.62 | 319.94 | 213.30 |
| Cost of varenicline ($) | 252.68 | 303.22 | 202.14 |
| Discount rate for LYs and QALYs (%) | 3.0 | 5.0 | 0.0 |
PTC proactive telephone calls, Web Web plus one proactive telephone call, PTC-Web Combination of PTC and Web behavioral treatment
aSix-month nonsmoking rates reduced by 5% to reflect estimated percentage of respondents whose self-reports would not be biochemically verified